miR‑96 exerts an oncogenic role in the progression of cervical cancer by targeting CAV‑1

Chen,Yong; Liu,Changqing; Xie,Bingfan; Chen,Shangqiu; Zhuang,Yuan; Zhang,Shaoxia

doi:10.3892/mmr.2020.11101

miR‑96 exerts an oncogenic role in the progression of cervical cancer by targeting CAV‑1

Authors:
- Yong Chen
- Changqing Liu
- Bingfan Xie
- Shangqiu Chen
- Yuan Zhuang
- Shaoxia Zhang
View Affiliations

Affiliations: Department of Gynecology, The Fifth Affiliated Hospital of Sun Yat‑sen University, Zhuhai, Guangdong 519000, P.R. China, Department of Ultrasonography, The Fifth Affiliated Hospital of Sun Yat‑sen University, Zhuhai, Guangdong 519000, P.R. China
Published online on: April 30, 2020 https://doi.org/10.3892/mmr.2020.11101
Pages: 543-550

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer is the 4th most common malignant tumor type affecting women worldwide; however, its molecular mechanisms are not fully understood. Previous studies have indicated that microRNAs (miRs) serve crucial roles in the cellular functions of tumors. miR‑96 is involved in the tumorigenesis of many cancer types. The aim of the present study was to investigate the role and mechanism of miR‑96 in the progression of cervical cancer. The present results suggested that overexpression of miR‑96 significantly enhanced the proliferative, migratory and invasive abilities of cervical cancer cells, while inhibiting miR‑96 had the opposite effects. Additionally, activation of the Akt/mTOR signaling pathway was enhanced by miR‑96 overexpression, while it was inhibited by the miR‑96 inhibitor. Moreover, it was identified that miR‑96 may directly target caveolin‑1 (CAV‑1) to decrease its expression level. Furthermore, overexpression of CAV‑1 could reverse the increase in cell proliferation, migration and invasion induced by miR‑96, as well as the upregulation of the Akt/mTOR signaling pathway. In conclusion, the present results suggested that miR‑96 may have an oncogenic role in the progression of cervical cancer by targeting CAV‑1. Therefore, miR‑96 may be a potential target for cervical cancer therapy.

View Figures

View References

1	Small W Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN and Gaffney DK: Cervical cancer: A global health crisis. Cancer. 123:2404–2412. 2017. View Article : Google Scholar : PubMed/NCBI
2	Xiao B, Xie Z, Guo L, Wu J and Zhang H: Stomatin-like protein 2 expression is associated with clinical survival in patients with cervical cancer. Int J Clin Exp Pathol. 8:1804–1809. 2015.PubMed/NCBI
3	de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al: Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 11:1048–1056. 2010. View Article : Google Scholar : PubMed/NCBI
4	Lecuru F, Bats A, Mathevet P, Querleu D, Leblanc E, Darai PM, Marret H, Collin C, Chatellier G and Gilaizeau F: Impact of sentinel lymph node biopsy on staging of early cervical cancer: Results of a prospective, multicenter study. J Clin Oncol. 27:CRA55062009. View Article : Google Scholar
5	Zhang Z, Wang J, Li J, Wang X and Song W: MicroRNA-150 promotes cell proliferation, migration, and invasion of cervical cancer through targeting PDCD4. Biomed Pharmacother. 97:511–517. 2017. View Article : Google Scholar : PubMed/NCBI
6	Gregory RI and Shiekhattar R: MicroRNA biogenesis and cancer. Cancer Res. 65:3509–3512. 2011. View Article : Google Scholar
7	Esquela-Kerscher A and Slack F: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
8	Li GC, Cao XY, Li YN, Qiu YY, Li YN, Liu XJ and Sun XX: MicroRNA-374b inhibits cervical cancer cell proliferation and induces apoptosis through the p38/ERK signaling pathway by binding to JAM-2. J Cell Physiol. 233:7379–7390. 2018. View Article : Google Scholar : PubMed/NCBI
9	Wang F, Shan S, Huo Y, Xie Z, Fang Y, Qi Z, Chen F, Li Y and Sun B: MiR-155-5p inhibits PDK1 and promotes autophagy via the mTOR pathway in cervical cancer. Int J Biochem Cell Biol. 99:91–99. 2018. View Article : Google Scholar : PubMed/NCBI
10	Kouji B, Iida M, Yanokura M, Kisu I, Iwata T, Tominaga E, Tanaka K and Aoki D: MicroRNA in cervical cancer: OncomiRs and tumor suppressor miRs in diagnosis and treatment. ScientificWorldJournal. 2014:1780752014.PubMed/NCBI
11	Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
12	Rasras S, Zibara K, Vosughi T and Zayeri Z: Genetics and epigenetics of glioblastoma: Therapeutic challenges. Clin Cancer Invest J. 7:43–49. 2018. View Article : Google Scholar
13	Takahashi RU, Prieto Vila M, Kohama I and Ochiya T: Development of microRNA-based therapeutic approaches for cancer patients. Cancer Sci. 110:1140–1147. 2019. View Article : Google Scholar : PubMed/NCBI
14	Chakraborty C, Sharma AR, Sharma G, Sarkar BK and Lee SS: The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer. Oncotarget. 9:10164–10174. 2018. View Article : Google Scholar : PubMed/NCBI
15	Mittal A, Chitkara D, Behrman SW and Mahato RI: Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials. 35:7077–7087. 2014. View Article : Google Scholar : PubMed/NCBI
16	Shi S, Han L, Deng L, Zhang Y, Shen H, Gong T, Zhang Z and Sun X: Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J Control Release. 194:228–237. 2014. View Article : Google Scholar : PubMed/NCBI
17	Testoni D, Hayashi M, Cohen-Wolkowiez M, Benjamin DK Jr, Lopes RD, Clark RH, Benjamin DK and Smith P: Late-onset bloodstream infections in hospitalized term infants. Pediatr Infect Dis J. 33:920–923. 2014. View Article : Google Scholar : PubMed/NCBI
18	Xie W, Sun F, Chen L and Cao X: MiR-96 promotes breast cancer metastasis by suppressing MTSS1. Oncol Lett. 15:3464–3471. 2018.PubMed/NCBI
19	Yang S, Chen Z, Fan D, Zhang R, Zhang Y and Wu S: MiR-182-5p and miR-96-5p increased hepatocellular carcinoma cell mobility, proliferation and cisplatin resistance partially by targeting RND3. RSC Advances. 8:34973–34983. 2018. View Article : Google Scholar
20	Fendler A, Jung M, Stephan C, Erbersdobler A, Jung K and Yousef GM: The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1. PLoS One. 8:e808072013. View Article : Google Scholar : PubMed/NCBI
21	He C, Zhang Q, Gu R, Lou Y and Liu W: miR-96 regulates migration and invasion of bladder cancer through epithelial-mesenchymal transition in response to transforming growth factor-β1. J Cell Biochem. 119:7807–7817. 2018. View Article : Google Scholar : PubMed/NCBI
22	Ma X, Shi W, Peng L, Qin X and Hui Y: MiR-96 enhances cellular proliferation and tumorigenicity of human cervical carcinoma cells through PTPN9. Saudi J Biol Sci. 25:863–867. 2018. View Article : Google Scholar : PubMed/NCBI
23	Sternberg PW and Schmid SL: Caveolin, cholesterol and Ras signalling. Nat Cell Biol. 1:E35–E37. 1999. View Article : Google Scholar : PubMed/NCBI
24	Yeong J, Thike AA, Ikeda M, Lim JCT, Lee B, Nakamura S, Iqbal J and Tan PH: Caveolin-1 expression as a prognostic marker in triple negative breast cancers of Asian women. J Clin Pathol. 71:161–167. 2017. View Article : Google Scholar : PubMed/NCBI
25	Duregon E, Senetta R, Bertero L, Bussolati B, Annaratone L, Pittaro A, Papotti M, Marchiò C and Cassoni P: Caveolin 1 expression favors tumor growth and is associated with poor survival in primary lung adenocarcinomas. Tumor Biol. 39:1010428317694312017. View Article : Google Scholar
26	Zhou W, He L, Dai Y, Zhang Y, Wang J and Liu B: MicroRNA-124 inhibits cell proliferation, invasion and migration by targeting CAV1 in bladder cancer. Exp Ther Med. 16:2811–2820. 2018.PubMed/NCBI
27	Butz H, Szabó PM, Khella HW, Nofech-Mozes R, Patocs A and Yousef GM: miRNA-target network reveals miR-124 as a key miRNA contributing to clear cell renal cell carcinoma aggressive behaviour by targeting CAV1 and FLOT1. Oncotarget. 6:12543–12557. 2015. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
29	Li JH, Liu S, Zhou H, Qu LH and Yang JH: Starbase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale clip-seq data. Nucleic Acids Res. 42((Database issue)): D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
30	Okada S, Raja SA, Okerblom J, Boddu A, Horikawa Y, Ray S, Okada H, Kawamura I, Murofushi Y, Murray F and Patel HH: Deletion of caveolin scaffolding domain alters cancer cell migration. Cell Cycle. 18:1268–1280. 2019. View Article : Google Scholar : PubMed/NCBI
31	Senetta R, Trevisan E, Rudà R, Maldi E, Molinaro L, Lefranc F, Chiusa L, Lanotte M, Soffietti R and Cassoni P: Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas. J Neuropathol Exp Neurol. 68:425–431. 2009. View Article : Google Scholar : PubMed/NCBI
32	Shatz M and Liscovitch M: Caveolin-1: A tumor-promoting role in human cancer. Int J Radiat Biol. 84:177–189. 2008. View Article : Google Scholar : PubMed/NCBI
33	Goetz J, Lajoie P, M Wiseman S and Nabi I: Caveolin-1 in tumor progression: The good, the bad and the ugly. Cancer Metastasis Rev. 27:715–735. 2008. View Article : Google Scholar : PubMed/NCBI
34	Martini M, De Santis M, Braccini L, Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
35	Yang N, Zhou J, Li Q, Han F and Yu Z: miR-96 exerts carcinogenic effect by activating AKT/GSK-3β/β-catenin signaling pathway through targeting inhibition of FOXO1 in hepatocellular carcinoma. Cancer Cell Int. 19:382019. View Article : Google Scholar : PubMed/NCBI
36	Song HM, Luo Y, Li DF, Wei CK, Hua KY, Song JL, Xu H, Maskey N and Fang L: MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells. Int J Clin Exp Pathol. 8:9889–9900. 2015.PubMed/NCBI